ABIONYX Announces the Publication of Pre-clinical Data in the Journal Metabolism Demonstrating that CER-001 Improves Lipid Pr...
15 Décembre 2020 - 7:26PM
Business Wire
- Beneficial effects on lipid profile and renal
function
- Reducing urinary albumin to creatinine ratio and restoring
nestin and nephrin content in the glomerulus
- A treatment option for patients with ultra-rare kidney
disease
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today announced the publication of a set of pre-clinical data in
the journal Metabolism demonstrating that CER-001 improves lipid
profile and kidney function in an emphasis kidney disease model
representative of LCAT (lecithin-cholesterol acyltransferase)
deficiency.
CER-001 is an HDL mimetic previously tested in different
pathological conditions, but never in a kidney disease prior to
ABIONYX Pharma's ATUn.
In a genetically modified mouse model of LCAT deficiency,
CER-001 had beneficial effects not only on lipid profile but also
on renal function, reducing urinary albumin to creatinine ratio and
restoring nestin and nephrin content in the glomerulus.
These new data give us a new opportunity for the use of CER-001
for the treatment of renal diseases. The company will continue to
work on strengthening the understanding the mechanism of action of
CER-001 in kidney disease.
“This publication in a reference journal in the field of
metabolism encourages us to continue exploring the effect of
CER-001. The removal of lipids from the kidney in an experimental
model of LCAT deficiency is a major breakthrough. Results are
consistent and really support a beneficial effect of CER-001 on the
kidney, the most affected organ in human LCAT deficiency,” said Dr.
Laura Calabresi, PhD., Professor of Pharmacology, University of
Milano, Department of Pharmacological and Biomolecular
Sciences.
This study was designed to investigate the catabolic fate of
CER-001, and to evaluate the effects of CER-001 on kidney disease.
Wild-type mice received CER-001 for 2 weeks. Plasma
lipid/lipoprotein profile and HDL subclasses were analyzed. In a
second set of experiments, mice were induced to develop the
ultra-rare renal LCAT disease and treated with CER-001. Lipid
profile, renal function, and kidney histology were evaluated.
As a conclusion, three major outcomes have emerged from this
study:
- Treatment with CER-001 ameliorates the dyslipidemia, reducing
plasma triglycerides and increasing HDL levels.
- More importantly, treatment with CER-001 ameliorates renal
function in a mouse model with ultra-rare renal disease, reducing
urinary albuminuria and restoring podocyte functionality.
- The data set the basis for the potential use of CER-001 in
other renal diseases.
This scientific publication, entitled “CER-001 ameliorates
lipid profile and kidney disease in a mouse model of Familial LCAT
Deficiency», is available online in the journal Metabolism:
https://www.metabolismjournal.com/article/S0026-0495(20)30328-0/fulltext
ABIONYX is awaiting data from other ongoing preclinical
studies.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients.
The biotech assets inherited from CERENIS Therapeutics constitute a
rich portfolio of valuable programs for the treatment of metabolic
diseases as well as with a HDL targeted drug delivery platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215006002/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024